3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
6
Squamous Cell Carcinoma of Head and Neck
2
Lymphoma, Follicular
2
Head and Neck Neoplasms
2
Recurrence
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell
1
Lymphoma
1
Hereditary Sensory and Autonomic Neuropathies
1
Hematologic Neoplasms
1
Interventions
Cyclophosphamide
15
romidepsin
9
Whole-Body Irradiation
9
fludarabine phosphate
8
Vincristine
8
Etoposide
8
Doxorubicin
8
Prednisone
7
Peripheral Blood Stem Cell Transplantation
7
Mycophenolic Acid
7
Brentuximab Vedotin
6
10-propargyl-10-deazaaminopterin
6
Rituximab
5
Granulocyte Colony-Stimulating Factor
5
Gemcitabine
5
Cyclosporine
5
denileukin diftitox
4
Nivolumab
4
Lenalidomide
4
mogamulizumab
3
Tacrolimus
3
Methotrexate
3
Immunohistochemistry
3
Gene Expression Profiling
3
Dexamethasone
3
Alemtuzumab
3
selinexor
2
pembrolizumab
2
pegfilgrastim
2
liposomal doxorubicin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Lymphoma, T-Cell, Peripheral
×
duvelisib
×
Clear all
NCT03372057
2025-03-07
PRIMO
SecuraBio
Phase 2
Completed
156 enrolled
21 charts